Intensity Therapeutics (INTS) reported second-quarter 2026 financial results and provided updates on its INT230-6 clinical programs. The company posted a net loss of $3.0 million for the quarter, compared with a net loss of $2.5 million in the same period of 2025.
The company said cash and cash equivalents totaled $9.5 million as of June 30, 2026. Intensity also reported activity to resume enrollment in select U.S. sites for the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and restarted patient treatment in the Phase 2 INVINCIBLE-4 triple negative breast cancer study.
- Research and development expenses were $1.8 million in Q2 2026, compared with $1.5 million a year earlier.
- General and administrative expenses were $1.3 million, compared with $1.2 million in Q2 2025.
- Net loss per share, basic and diluted, was $1.11 for the quarter, compared with $3.36 a year earlier.
- The company raised net proceeds of $1.6 million under its at-the-market facility during the second quarter and an additional $1.3 million after June 30, 2026.
- Preliminary INVINCIBLE-4 data from 14 patients showed a 71% pathological complete response rate in Cohort A and 42% in Cohort B.
$INTS Hedge Fund Activity
We have seen 5 institutional investors add shares of $INTS stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SAPIENT CAPITAL LLC removed 624,145 shares (-96.0%) from their portfolio in Q1 2026, for an estimated $3,669,972
- KMT WEALTH MANAGEMENT, LLC added 496,493 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,035,621
- ROTHSCHILD WEALTH LLC removed 472,616 shares (-95.3%) from their portfolio in Q1 2026, for an estimated $2,778,982
- GEODE CAPITAL MANAGEMENT, LLC removed 434,229 shares (-94.3%) from their portfolio in Q1 2026, for an estimated $2,553,266
- LEGACY ADVISORS, LLC removed 153,447 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $902,268
- CREATIVE PLANNING removed 143,136 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $841,639
- STATE STREET CORP removed 136,200 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $800,856
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
